UK SME with novel wound diagnostic kits seeks European distributors

A UK SME has developed novel wound diagnostic kits that detect elevated host protease activity (EPA) and bacterial protease activity (BPA) that enables a more effective treatment regime to be undertaken. The products offer significant potential savings for health services when this diagnostic capability is correctly implemented into their woundcare protocols. The company is looking for partners via a distribution services agreement within identified European markets.

This North of England SME was formed in order to improve therapeutic outcomes in wound healthcare. Ineffective wound care is estimated to cost health services $20-25bn annually. This novel product offers insight into the state of the wound so that the doctor can take the correct course of action. Elevated Protease Activity (EPA) and bacterial protease activity (BPA) are undetectable without testing and the tests take only fifteen minutes to obtain a result. The product is CE marked and the company has evidence of effectiveness. The company is looking for distributors in European markets via a distribution services agreement.